Consumers, health care professionals, and even policymakers lack high-quality, up-to-date information about where pharmaceuticals are made or the quality of the manufacturing facilities.
This is a critical public health issue, due to large variations in manufacturing quality as well as supply chain vulnerability to extreme weather, pandemic, trade, and geopolitical disruptions.
For the first time, that’s changing. Pharm3r’s QRx both maps the global supply chain and ranks product and facility manufacturing quality.
Our latest paper with Randy Hatton University of Florida College of Pharmacy documents a decade of increased offshoring highlights specific areas of supply chain vulnerability and calls for full manufacturing and location transparency for all consumers.
